Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 12, Number 6—June 2006

Research

Co-infections of Adenovirus Species in Previously Vaccinated Patients

Gary J. Vora*†1, Baochuan Lin*†1, Kevin Gratwick‡, Carolyn Meador§, Christian Hansen‡, Clark Tibbetts†, David A. Stenger*†, Marina Irvine‡, Donald Seto†¶, Anjan Purkayastha†¶, Nikki E. Freed‡, Marylou G. Gibson#, Kevin Russell†‡, and David Metzgar†‡Comments to Author 
Author affiliations: *Naval Research Laboratory, Washington, DC, USA; †Epidemic Outbreak Surveillance Consortium, Falls Church, Virginia, USA; ‡Naval Health Research Center, San Diego, California, USA; §Nova Research Inc., Alexandria, Virginia, USA; ¶George Mason University, Manassas, Virginia, USA; #Virapur, LLC, San Diego, California, USA

Main Article

Table 1

Naval Health Research Center data for molecular detection of adenoviral co-infections in vaccinated and unvaccinated patients with febrile respiratory illness*

Original designation† Vaccination date Microneu-tralization‡ Multiplex PCR Species-specific PCR (B, C, E) Sequencing§ GenBank accession no.
7151.AV5.V.98.FJ 5 Nov 1997 4 B, C B, C, E 5, 21 AY337237
7137.AV4.V.97.FJ 1 Dec 1997 4 E B, E 4 variant
7274.AV4.V.98.FJ 11 Feb 1998 4 E, B E, B 4 vaccine (Δ = 2) AF065062
7307.AV5.V.98.FJ 9 Feb 1998 4 C, B B, C, E 5
7333.AV4.V.98.FJ 25 Mar 1998 4 E E, B 4 variant AY337242
4185.AV4.V.97.FLW 24 Mar 1997 4 E B, E 4 variant, 7h AY337252
4476.AV4.V.97.FLW 24 Oct 1997 4 E B, E 4 variant AY337249
79.AV4.V.96.GL 7 Oct 1996 4 E E 4 vaccine (Δ = 3) AF065062
141.AV7.V.96.GL 12 Nov 1996 7 B B 7d2 (prototype) AY337258
275.AV4.V.97.GL 31 Jan 1997 4 E E 4 vaccine (Δ = 3) AY337239
1212.AV7.V.97.GL 29 Sep 1997 7 B B, E 7d2 (Δ = 2) AY337255
1108.AV7.V..97.GL 8 Oct 1997 7 E, B B, E 7 vaccine (Δ = 0) AF065067
1122.AV7.V.97.GL 8 Oct 1997 7 B B 7d2 (Δ = 2) AF321311
1150.AV7.V.97.GL 8 Oct 1997 7 B B, E 7 vaccine (Δ = 2) AY337254
1152.AV7.V.97.GL 8 Oct 1997 7 B B 7 vaccine (Δ = 1) AY337253
1186.AV7.V.97.GL 8 Oct 1997 7 B B, E 7d2 (Δ = 2) AF321311
1251.AV7.V.97.GL 8 Oct 1997 7 B B 7d2 (Δ = 2) AF321311
1275.AV7.V.97.GL 8 Oct 1997 7 B B, E 7 vaccine (Δ = 1) AY337257
1302.AV7.V.97.GL 8 Oct 1997 7 B B, E 7 vaccine (Δ = 2) AY337256
1649.AV7.V.98.GL 13 Jan 1998 7 B B 7d2 (Δ = 2) AF321311
1856.AV5.V.98.GL 25 Mar 1998 4 C B, C, E 5, 7h
60406.AV7.99.FB 7 B B 7 vaccine (Δ = 2) AY337256
60673.AV4.00.FB 4 E E 4 variant AY337237
60691.AV4.00.FB 4 E E, B 4 variant AY337238
60697.AV4.00.FB 4 E E 4 variant AY337246
60708.AV4.00.FB 4 E E 4 variant AY337237
60716.AV4.00.FB 4 E E 4 variant AY337247
CHPPM2.AV4.00.FB E E, B 4 variant AY337237
CHPPM9.AV4.00.FB 4 E E, B 4 variant AY337237
CHPPM13.AV4.00.FB E E, B 4 variant AY337237
CHPPM29.AV4.00.FB 4 E E 4 variant AY337237
CHPPM44.AV4.00.FB 4 E E 4 variant AY337237
7372.AV5.98.FJ 4 C B, C, E 5, 7h
40098.AV4.98.FJ 4 E E 4 variant AY337241
40160.AV4.98.FJ 4 E E, B 4 variant AY337237
40183.AV4.98.FJ 4 E E 4 variant AY337237
40781.AV4.99.FJ 4 E E 4 variant AY337238
40844.AV4.99.FJ 4 E E 4 variant AY337237
41059.AV4.99.FJ 4 E E 4 variant AY337237
10060.AV4.98.GL E E 4 variant AY337237
10190.AV4.98.GL 4 E E, B 4 variant AY337237
10206.AV4.98.GL 4 E E 4 variant AY337244
10213.AV4.98.GL 4 E E 4 variant AY337240
10257.AV4.98.GL 4 E E 4 variant AY337237
10258.AV4.98.GL 4 E E 4 variant AY337237
10756.AV4.00.GL 4 E E 4 variant AY337243
50108.AV4.00.LAC E B, E 4 variant AY337251
20044.AV4.98.MCRD 4 E B, E 4 variant AY337248
20139.AV4.98.MCRD E E 4 variant AY337237
20142.AV4.98.MCRD E E 4 variant AY337250
20143.AV4.98.MCRD E E, B 4 variant AY337237
20145.AV4.98.MCRD E E 4 variant AY337245

*PCR, polymerase chain reaction. Letters or numbers in boldface indicate weak positives.
†Acquisition number, serotype, isolation year, and isolation location.
‡Results are listed as serotypes. Species B1 includes serotypes 3, 7, 16, 21; species C includes serotypes 1, 2, 5, 6; and species E includes serotype 4.
§Variant/vaccine grouping based on the hexon gene sequence defined by Blasiole et al. (16). Δ = # reflects number of base substitutions from vaccine strain in 1,490 bp of the hexon sequence (16). The 7d2 designation is based on that of Blasiole et al. (16). The 7h designation based on fiber gene sequence is as defined by Kajon and Wadell (17).

Main Article

1These authors contributed equally to this article.

2The members of the Epidemic Outbreak Surveillance Consortium are Peter F. Demitry, Theresa Lynn Difato, Robb K. Rowley, Clark Tibbetts, Eric H. Hanson, Rosana R. Holliday, Curtis White, David A. Stenger, Donald Seto, Elizabeth A. Walter, Jerry Diao, Brian K. Agan, Kevin Russell, David Metzgar, Gary J.Vora, Baochuan Lin, Dzung Thach, Jing Su, Chris Olsen, Dong Xia, John Gomez, John McGraw, Linda Canas, Margaret Jesse, Mi Ha Yuen, Robert Crawford, Sue A. Worthy, Sue Ditty, John McGraw, Michael Jenkins, Zheng Wang, Cheryl J. James, Kathy Ward, Kenya Grant, and Kindra Nix.

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO